Compare COSM & ASBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COSM | ASBP |
|---|---|---|
| Founded | 2009 | 2021 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Pharmaceuticals | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.1M | 18.9M |
| IPO Year | 2013 | N/A |
| Metric | COSM | ASBP |
|---|---|---|
| Price | $0.46 | $0.09 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 500.5K | ★ 69.9M |
| Earning Date | 11-17-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $59,792,819.00 | $1,941.00 |
| Revenue This Year | $28.14 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.69 | N/A |
| 52 Week Low | $0.28 | $0.08 |
| 52 Week High | $1.32 | $15.80 |
| Indicator | COSM | ASBP |
|---|---|---|
| Relative Strength Index (RSI) | 23.98 | 27.96 |
| Support Level | $0.56 | $0.08 |
| Resistance Level | $0.66 | $0.10 |
| Average True Range (ATR) | 0.07 | 0.01 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 1.47 | 25.00 |
Cosmos Health Inc is engaged in the nutraceuticals sector through its own proprietary lines of products 'Sky Premium Life' and 'Mediterranation'. Additionally, the firm is operating in the pharmaceutical sector through the provision of a broad line of branded over-the-counter drugs and branded and generic medicines. The company's focus will be on Branded Pharmaceuticals, Over-the-Counter medicines, and Generic Pharmaceuticals. It provides its products to wholesale drug distributors, wholesalers, and retail healthcare providers. The company's segment are Wholesale, Pharma Manufacturing, Nutraceuticals & Pharmaceuticals and Other. It derives maximum revenue from Wholesale Segment.
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.